Cantor Fitzgerald Comments on Collegium Pharmaceutical Inc’s FY2020 Earnings (NASDAQ:COLL)
Collegium Pharmaceutical Inc (NASDAQ:COLL) – Equities research analysts at Cantor Fitzgerald cut their FY2020 earnings per share estimates for shares of Collegium Pharmaceutical in a report released on Thursday, August 8th. Cantor Fitzgerald analyst B. Folkes now anticipates that the specialty pharmaceutical company will earn $0.34 per share for the year, down from their prior estimate of $0.44. Cantor Fitzgerald has a “Overweight” rating and a $24.00 price target on the stock.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.05. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The company had revenue of $75.04 million during the quarter, compared to the consensus estimate of $75.77 million. During the same period last year, the business posted ($0.40) earnings per share. Collegium Pharmaceutical’s revenue was up 2.7% on a year-over-year basis.
Shares of COLL stock opened at $11.82 on Monday. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 0.23. Collegium Pharmaceutical has a 52-week low of $10.01 and a 52-week high of $19.83. The stock has a market capitalization of $392.94 million, a P/E ratio of -9.93 and a beta of 0.54. The stock has a fifty day simple moving average of $11.53.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. MERIAN GLOBAL INVESTORS UK Ltd purchased a new position in Collegium Pharmaceutical in the first quarter valued at $26,000. First Quadrant L P CA purchased a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $36,000. BNP Paribas Arbitrage SA increased its stake in Collegium Pharmaceutical by 67,855.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock worth $93,000 after buying an additional 6,107 shares during the period. Paradigm Capital Management Inc. NY purchased a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $131,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $137,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $11.26, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 132,069 shares in the company, valued at $1,487,096.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 2,857 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $12.31, for a total transaction of $35,169.67. Following the transaction, the executive vice president now owns 40,596 shares in the company, valued at $499,736.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,144 shares of company stock worth $754,506. Corporate insiders own 8.08% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: Hedge Funds – How They Work For Investors
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.